ADAR1 Capital Management »

Prelude Therapeutics shares owned by ADAR1 Capital Management

Quarter-by-quarter ownership of Prelude Therapeutics (PRLD) shares owned by ADAR1 Capital Management from 13F filings

Historical chart of ADAR1 Capital Management investment in Prelude Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Prelude Therapeutics held by ADAR1 Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Prelude Therapeutics by ADAR1 Capital Management

Quarter filed Position value Share count Share price at filing
2026-03-31 $523k 153k 3.42

More positions owned by ADAR1 Capital Management

Abivax Sa Sponsored Ads (ABVX)
Protagonist Therapeutics (PTGX)
Roivant Sciences SHS (ROIV)
Immunovant (IMVT)
Terns Pharmaceuticals Call Option (TERN)
State Str Spdr S&p 500 Etf T Tr Unit (SPY)
Cytokinetics Com New (CYTK)
Crinetics Pharmaceuticals In (CRNX)
Ea Series Trust Alpha Arch 1-3 (BOXX)
Denali Therapeutics (DNLI)
Beam Therapeutics (BEAM)
Zai Lab Adr (ZLAB)
Septerna (SEPN)
Vir Biotechnology (VIR)
Dbv Technologies S A Sponsored Ads (DBVT)

View all positions for ADAR1 Capital Management

Top funds holding Prelude Therapeutics

OrbiMed Advisors
Baker Bros. Advisors
Kynam Capital Management
Vanguard Group
Vanguard Capital Management
EcoR1 Capital
Two Sigma Investments
Sphera Funds Management
Acadian Asset Management
Millennium Management
Morgan Stanley
BlackRock
Geode Capital Management
Marshall Wace
Renaissance Technologies

View all funds holding Prelude Therapeutics